Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTA), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. reports news centered on PAS-004, its next-generation macrocyclic MEK inhibitor, and the company’s clinical-stage biotechnology operations. Recurring updates cover NF1-associated plexiform and cutaneous neurofibromas, advanced cancer, ALS-related research, FDA designations, clinical development strategy and medical leadership.
Company news also includes capital actions, investor conference presentations and public-company matters tied to common stock and warrant securities. Pasithea’s releases frame the business around drug-development progress, regulatory designations and financing activity supporting research, preclinical work and clinical trials.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a collaboration with musician DJ Carlita to create customized music playlists for patients undergoing intravenous ketamine infusion therapy. This initiative aims to enhance the therapeutic experience, building on research that supports the efficacy of music in psychedelic therapy. Pasithea has recently opened its first clinic in the UK and will offer in-home treatments in the US. Ketamine, an FDA-approved anesthetic, is being repurposed to treat conditions like treatment-resistant depression and PTSD with rapid and sustained effects.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has formed a new Scientific Advisory Board (SAB) to guide its efforts in developing treatments for mental health and brain disorders. The SAB will be chaired by esteemed psychiatrist Charles Nemeroff, M.D., Ph.D., who brings extensive expertise in psychiatry and neuropsychopharmacology. This move aims to enhance Pasithea’s credibility and advance its research on novel treatments targeting psychiatric and neurological conditions. The company is committed to addressing the growing mental health crisis through innovative drug development.
Pasithea Clinics has launched IV ketamine infusion therapy in Knightsbridge, London, targeting mental health disorders. This initiative is part of Pasithea Therapeutics Corp.'s broader mission to find effective treatments for psychiatric conditions. The therapy is particularly aimed at treatment-resistant depression and PTSD, with studies indicating a clinical response rate of up to 70%. Partnering with ZEN Healthcare in the U.K. and The IV Doc in the U.S., Pasithea is expanding access to these treatments, addressing the growing mental health crisis.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a partnership with ZEN Healthcare to launch ketamine infusion therapy in Central London for patients with treatment-resistant mental health disorders. This initiative aims to address the growing need for innovative treatments amid rising mental health cases exacerbated by the pandemic. The therapy promises rapid efficacy in conditions like treatment-resistant depression and PTSD. Pasithea recently raised $24 million during its IPO, enhancing its capacity to expand treatment networks in the U.K. and the U.S.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a collaboration with Evotec, a leading drug development company, to advance its initial drug candidate targeting psychiatric disorders. This partnership marks the start of a new chemical entity development program focused on neuroinflammatory pathways linked to depression and schizophrenia. The collaboration aims to leverage Evotec's expertise to expedite the drug's progression toward clinical trials. The company's strategic focus is on developing innovative treatments for psychiatric conditions and establishing psychiatric clinics in the UK and US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that CEO Dr. Tiago Reis Marques will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 10:10 AM ET. The live presentation will be available via webcast and archived for 30 days on the company's website. Pasithea focuses on developing treatments for psychiatric and neurological disorders, targeting pathophysiology to improve efficacy and tolerability compared to conventional therapies. The company also provides business support services for anti-depression clinics in the UK and the US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has successfully closed its initial public offering of 4,800,000 units at a price of $5.00 per unit, generating approximately $24.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant for an additional share. The company's stock and warrants began trading on Nasdaq on September 15, 2021. The offering aims to support the company’s focus on discovering new treatments for psychiatric and neurological disorders.